ZYNTEGLO™ (betibeglogene autotemcel) | An FDA Approved …
ZYNTEGLO ™ is an FDA-approved gene therapy that has the potential to free people with beta-thalassemia from regular transfusions. In two phase 3 studies, about 9 out of 10 (89%; 32/36 …
新药 | 美国FDA批准首款β-地中海贫血基因疗法Zynteglo上市 - 知乎
2022 年 8 月 17 日，美国食品和药物管理局FDA批准了蓝鸟生物公司 Zynteglo（betibeglogene autotemcel，beti-cel），这是第一个基于细胞的基因疗法，用于治疗需要定期输血的成人和儿 …
ZYNTEGLO is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell …
Betibeglogene autotemcel - Wikipedia
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [ 1 ] [ 5 ] [ 2 ] It was developed by Bluebird Bio and was given …
ZYNTEGLO | FDA - U.S. Food and Drug Administration
Tradename: ZYNTEGLO Manufacturer: bluebird bio Inc. Indication: For treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell (RBC) transfusions; …
280万美元！世界最昂贵药物诞生：FDA批准首个β-地贫慢病毒疗法|地中海贫血|贫慢病毒|珠蛋白链|FDA|批准|获批|Zynteglo…
2022年8月19日 · Zynteglo 是一款基于 bluebird bio 的 LentiGlobin 平台的的慢病毒基因疗法，是一种单次给药的基因治疗产品， 首先从患者骨髓中提取造血干细胞，然后通过慢病毒将β-珠蛋白 …
ZYNTEGLO™ (betibeglogene autotemcel) Treatment Journey
ZYNTEGLO is a one-time gene therapy to treat beta-thalassemia (also known as beta-thalassemia major or Cooley’s Anemia) in patients who require regular transfusions. Beta …
ZYNTEGLO | Boston Children's Hospital
ZYNTEGLO™, also called beti-cel (betibeglogene autotemcel), is a one-time gene therapy for beta thalassemia.It was approved by the U.S. Food and Drug Administration (FDA) in 2022 for …
全球首个β地中海贫血基因疗法上市！蓝鸟生物在德推Zynteglo
2020年1月16日 · 近日，该公司宣布，在德国推出Zynteglo（LentiGlobin，含βA-T87Q珠蛋白编码基因的自体CD34+细胞），这是一种一次性的基因疗法，用于适合造血干细胞（HSC）移植 …
全球β地中海贫血基因疗法！蓝鸟生物Zynteglo获美国FDA优先审 …
Zynteglo有望提供一种取代标准护理疗法（定期RBC输注+铁螯合）的治疗方案。 Zynteglo是一种一次性基因疗法，开发用于治疗β-地中海贫血和镰状细胞病 ...